Delving into the Latest Updates on Mallinckrodt Pharmaceuticals Ireland Ltd. with Synapse

Compatibility and Safety Implications Associated with Interfacing Medical Devices in Neonatal Respiratory Care: A Case Example Using the Inhaled Nitric Oxide Delivery System

Review

作者: DeWitt, Anthony L ; Potenziano, Jim L ; Acker, Jaron ; Schmidt, Jeffrey M ; Larkin, Thomas A

Over the past decade, international organizations have instituted strict regulations for the safe use of connected medical devices. The International Organization for Standardization and the Medical Device Single Audit Program instituted certifications to ensure that connected devices are compatible and operate within their proper clinical parameters. These efforts came about, in part, as a consequence of clinicians' decisions to use nonstandard, modified, or improvised devices for purposes outside the original manufacturers' approved parameters. Unapproved device modifications can be associated with increased risk of dosing errors, monitoring errors, tubing misconnections and serious or potentially fatal adverse events; furthermore, health care providers who implement unapproved device modifications may assume legal and financial liability should harm come to patients as a consequence of the modification. Using the inhaled nitric oxide delivery system as an example, the objective of this paper is to raise awareness of the potential dangers associated with unapproved modification and interfacing of therapeutic gas delivery systems and ventilators in the neonatal intensive care unit setting. The paper also highlights the rationale and necessity for rigorous validation processes that ensure that interfaced medical devices perform as intended in the clinical setting.

100 项与 Mallinckrodt Pharmaceuticals Ireland Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Mallinckrodt Pharmaceuticals Ireland Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

醋酸特利加压素 ( AVPR1A x AVPR1B x AVPR2 )	肝肾综合征更多	批准上市
Human Fibrinogen / Human Thrombin(Mallinckrodt Pharmaceuticals Ireland Limited)	凝血障碍更多	撤市